JP2008501034A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501034A5
JP2008501034A5 JP2007515456A JP2007515456A JP2008501034A5 JP 2008501034 A5 JP2008501034 A5 JP 2008501034A5 JP 2007515456 A JP2007515456 A JP 2007515456A JP 2007515456 A JP2007515456 A JP 2007515456A JP 2008501034 A5 JP2008501034 A5 JP 2008501034A5
Authority
JP
Japan
Prior art keywords
formulation
buffer system
posaconazole
agent
microns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007515456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501034A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/018945 external-priority patent/WO2005117831A1/en
Publication of JP2008501034A publication Critical patent/JP2008501034A/ja
Publication of JP2008501034A5 publication Critical patent/JP2008501034A5/ja
Withdrawn legal-status Critical Current

Links

JP2007515456A 2004-05-28 2005-05-27 ポサコナゾールを含む注射用薬学的懸濁液 Withdrawn JP2008501034A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57512604P 2004-05-28 2004-05-28
PCT/US2005/018945 WO2005117831A1 (en) 2004-05-28 2005-05-27 Injectable pharmaceutical suspension comprising posaconazole

Publications (2)

Publication Number Publication Date
JP2008501034A JP2008501034A (ja) 2008-01-17
JP2008501034A5 true JP2008501034A5 (cg-RX-API-DMAC7.html) 2008-07-03

Family

ID=34971355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515456A Withdrawn JP2008501034A (ja) 2004-05-28 2005-05-27 ポサコナゾールを含む注射用薬学的懸濁液

Country Status (15)

Country Link
EP (1) EP1761247A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008501034A (cg-RX-API-DMAC7.html)
KR (1) KR20070027564A (cg-RX-API-DMAC7.html)
CN (1) CN1988887A (cg-RX-API-DMAC7.html)
AR (1) AR049063A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005249502A1 (cg-RX-API-DMAC7.html)
CA (1) CA2567803A1 (cg-RX-API-DMAC7.html)
IL (1) IL179627A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06013886A (cg-RX-API-DMAC7.html)
NO (1) NO20066005L (cg-RX-API-DMAC7.html)
PE (1) PE20060291A1 (cg-RX-API-DMAC7.html)
RU (1) RU2006146555A (cg-RX-API-DMAC7.html)
TW (1) TWI290051B (cg-RX-API-DMAC7.html)
WO (1) WO2005117831A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200609890B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009469A1 (en) * 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
WO2007131253A2 (de) 2006-05-12 2007-11-22 Pharmacon-Forschung Und Beratung Gmbh Verwendung von kombinationspräparaten, umfassend antimykotika
EP2130540A1 (en) * 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
EP2141159A1 (en) 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
CA2767489A1 (en) 2009-07-09 2011-01-13 Sandoz Ag A crystalline form of posaconazole
US9073904B2 (en) 2010-05-19 2015-07-07 Sandoz Ag Preparation of posaconazole intermediates
EP2571847B1 (en) 2010-05-19 2016-09-21 Sandoz AG Process for the preparation of chiral hydrazides
CN102892763B (zh) 2010-05-19 2016-03-09 桑多斯股份公司 泊沙康唑及泊沙康唑中间体的纯化
AU2011254654B2 (en) 2010-05-19 2016-01-07 Sandoz Ag Process for the preparation of chiral triazolones
PL3391890T3 (pl) * 2010-06-29 2021-12-20 Merck Sharp & Dohme Corp. Preparaty dożylnego roztworu pozakonazolu stabilizowane podstawioną beta-cyklodekstryną
CN103635465A (zh) 2011-06-16 2014-03-12 桑多斯股份公司 制备手性化合物的方法
CN103284959B (zh) * 2012-02-22 2015-06-03 重庆圣华曦药业股份有限公司 泊沙康唑冻干粉针剂及制备方法
CN102755628B (zh) * 2012-07-16 2013-10-23 中国科学院微生物研究所 一种抗真菌的药物组合物
CN102805731B (zh) * 2012-08-22 2014-04-30 北京莱瑞森医药科技有限公司 泊沙康唑干混悬剂及其制备方法
CN105030668B (zh) * 2015-06-26 2018-03-27 济川药业集团有限公司 泊沙康唑口服混悬剂及其制备方法
CN106333925B (zh) * 2015-07-10 2019-06-18 上海美悦生物科技发展有限公司 一种泊沙康唑液体混悬剂及其制备方法
CN105997872B (zh) * 2016-07-08 2019-02-19 河南省立眼科医院 一种含有泊沙康唑的眼用纳米胶束抗真菌溶液
CN110582264B (zh) * 2017-03-26 2022-11-11 V·R·斯塔福德 眼睑皮肤状况的处理方法
AU2018253189A1 (en) * 2017-04-12 2019-12-05 Vikash J. BHAGWANDIN Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors
CN110507609B (zh) * 2018-05-21 2021-09-17 上海医药工业研究院 泊沙康唑口服混悬剂的制备方法
CN111514146A (zh) * 2020-04-28 2020-08-11 山西振东泰盛制药有限公司 含有泊沙康唑的药物组合物
CN113933131B (zh) * 2021-09-24 2024-01-26 合肥天一生物技术研究所有限责任公司 一种阴道微生物荧光染色液

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
PL212985B1 (pl) * 2001-04-03 2012-12-31 Schering Corp Ciekla zawiesina zawierajaca przeciwgrzybiczo skuteczna ilosc posakonazolu oraz zastosowanie zmikronizowanych czastek posakonazolu

Similar Documents

Publication Publication Date Title
ES2875584T3 (es) Formulación para inhalación líquida que comprende RPL554
US5648399A (en) Liquid polymer composition and method of use
ES2671342T3 (es) Antibióticos nebulizados para terapia de inhalación
US20210015748A1 (en) Topical formulations having enhanced bioavailability
JP2013067643A (ja) 動物における障害を治療および予防するための薬剤組成物の経粘膜投与
EA200501001A1 (ru) Фармацевтический состав с нерастворимым активным агентом
US12150923B2 (en) Methods and compositions for treating edema refractory to oral diuretics
JPH03128316A (ja) 液体重合体組成物及びその使用方法
CA2467611A1 (en) Azithromycin dosage forms with reduced side effects
ES2928399T3 (es) Composición farmacéutica bactericida que comprende ibuprofeno
SK16432003A3 (sk) Aerosólový prostriedok a spôsob jeho výroby
US20220151944A1 (en) Fluorouracil-containing formulations
US12396976B2 (en) Formulations having anti-inflammatory activity and antimicrobial activity against gram-positive bacteria
WO2025141531A1 (en) Inhalation formulation of amoxicillin clavulanate
ES3055646T3 (en) Microbial removal
ES2918193T3 (es) Polvo medicamentoso para administración por inhalación y un proceso del mismo
JP2006518719A (ja) ヘルペスの治療のためのpvp−ヨウ素リポソームの使用
WO2022074630A1 (en) Liquid oral suspension of favipiravir
JP2007509949A (ja) 薬理学的に活性な化合物の塩
BHAGWAT et al. Nanostrategies for Infectious Pulmonary Diseases: Current Progress and Future Prospects
WO2025017382A1 (en) Azithromycin nasal spray formulation
Moskowitz Treatment of a Canine Oral Papilloma With Topical Molecular Iodine: A Case Report With Implications for Antiviral Therapy in Humans
WO2024182528A2 (en) Encapsulated liposomal nanoformulations
WO2025005804A1 (en) Mucoadhesive formulation
García Canclini et al. Ibuprofen, a traditional drug that may impact the course of COVID-19 new effective formulation in nebulizable solution